Contraceptive efficacy and safety of DMPA-SC

Contraception. 2004 Oct;70(4):269-75. doi: 10.1016/j.contraception.2004.06.011.


DMPA-SC 104 mg/0.65 mL is a new, low-dose subcutaneous (SC) formulation of Depo-Provera contraceptive injection (150 mg/mL medroxyprogesterone acetate injectable suspension) that provides efficacy, safety and immediacy of onset equivalent to Depo-Provera intramuscular (IM) injection. Two large, open-label, Phase 3 studies assessed the 1-year contraceptive efficacy, safety and patient satisfaction with DMPA-SC administered every 3 months (12-13 weeks). Zero pregnancies were reported in both studies, which included a total of 16,023 woman-cycles of exposure to DMPA-SC and substantial numbers of overweight or obese women. DMPA-SC was well-tolerated and adverse events were similar to those reported previously with Depo-Provera IM. Thus, DMPA-SC offers women a new, highly effective and convenient long-acting contraceptive option.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III

MeSH terms

  • Adult
  • Amenorrhea / epidemiology
  • Asia
  • Blood Pressure
  • Body Mass Index
  • Body Weight
  • Contraceptive Agents, Female / administration & dosage*
  • Contraceptive Agents, Female / adverse effects*
  • Europe
  • Female
  • Humans
  • Injections, Subcutaneous
  • Medroxyprogesterone Acetate / administration & dosage*
  • Medroxyprogesterone Acetate / adverse effects*
  • Patient Satisfaction
  • Pregnancy
  • United States
  • Uterine Hemorrhage / epidemiology


  • Contraceptive Agents, Female
  • Medroxyprogesterone Acetate